Loading clinical trials...
Loading clinical trials...
This study will test the hypothesis that GW427353, a beta-3 adrenergic agonist, retards the emptying of the colon and increases total colonic transit time.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
GlaxoSmithKline
NCT07481422 · Irritable Bowel Syndrome (IBS)
NCT07283341 · Irritable Bowel Syndrome (IBS)
NCT04506593 · Eosinophilic Esophagitis, Gastroesophageal Reflux Disease (GERD), and more
NCT07345377 · Irritable Bowel Syndrome (IBS), Pain, and more
NCT06657001 · Inflammatory Bowel Disease (IBD), Irritable Bowel Syndrome (IBS), and more
GSK Investigational Site
Rochester, Minnesota
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions